Immunotherapy before surgery for early-stage colon cancer
Part of Cancer, Digestive system clinical trials.
This study tests giving an immunotherapy drug (pembrolizumab) before surgery for people with early-stage colon cancer that has a specific genetic feature. The goal is to see if the drug can shrink the tumor enough to avoid more extensive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have colon cancer that is at an early to moderate stage (stage I, II, or III).
- Your tumor has a specific genetic feature called dMMR (which may make it respond well to immunotherapy).
- You are healthy enough to have surgery, and you are planning to have it.
- You are not allergic to pembrolizumab (the study drug).
- You do not need emergency surgery for a blocked bowel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and porustobart) given before surgery for colon cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can shrink or eliminate colon tumors in people with dMMR/MSI-high cancer, possibly allowing some to avoid surgery. It is for patients whose cancer has not spread.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
This Phase 2 trial tests immune “checkpoint” medicines (and combinations) given before colon surgery to see if they can better control early colon cancer. It is aimed at people with non-metastatic colon cancer and certain tumor markers.
This trial tests two immunotherapy drugs (ADG126 and pembrolizumab) given before surgery for locally advanced colorectal cancer that hasn't spread. It aims to shrink tumors and improve outcomes.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new DMMR Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.